Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bazedoxifene Acetate

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Bazedoxifene Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bazedoxifene Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bazedoxifene Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

    NCT00847821 · start 2009-05

    Registered record
    Registry ID
    NCT00847821
    Conditions
    Postmenopause
    Interventions
    Bazedoxifene 10 mg/CE 0.625 mg; Bazedoxifene 20 mg/CE 0.625 mg; Bazedoxifene 40 mg/CE 0.625 mg; Bazedoxifene 10 mg/CE 0.45 mg; Bazedoxifene 20 mg/CE 0.45 mg; Bazedoxifene 40 mg/CE 0.45 mg; Raloxifene 60 mg; Placebo
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2009-05
    Completion
    2010-08
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause
    InterventionBazedoxifene 10 mg/CE 0.625 mg; Bazedoxifene 20 mg/CE 0.625 mg; Bazedoxifene 40 mg/CE 0.625 mg; Bazedoxifene 10 mg/CE 0.45 mg +4 more
    PhaseNot recorded
    Registry statusTerminated

  • Study Evaluating Changes In Mammographic Breast Density

    NCT00774267 · start 2009-01

    Registered record
    Registry ID
    NCT00774267
    Conditions
    Osteoporosis
    Interventions
    BZA 20 mg/CE 0.45 mg; BZA 20 mg/CE 0.625 mg; Raloxifene 60 mg; Placebo
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-04
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionBZA 20 mg/CE 0.45 mg; BZA 20 mg/CE 0.625 mg; Raloxifene 60 mg; Placebo
    PhaseNot recorded
    Registry statusCompleted

  • Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

    NCT00808132 · start 2009-01

    Registered record
    Registry ID
    NCT00808132
    Conditions
    Menopause; Osteoporosis
    Interventions
    bazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; bazedoxifene 20 mg; conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-01
    Completion
    2011-02
    Enrolment
    1,886

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Osteoporosis
    Interventionbazedoxifene 20 mg/ conjugated estrogens 0.45 mg; bazedoxifene 20 mg/ conjugated estrogens 0.625 mg; bazedoxifene 20 mg; conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg +1 more
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Premarin and Bazedoxifene Potential Interaction

    NCT00745173 · start 2008-09

    Registered record
    Registry ID
    NCT00745173
    Conditions
    Postmenopause
    Interventions
    Premarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause
    InterventionPremarin
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women

    NCT00706225 · start 2008-06

    Registered record
    Registry ID
    NCT00706225
    Conditions
    Postmenopause
    Interventions
    Bazedoxifene and conjugated estrogens
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    2008-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause
    InterventionBazedoxifene and conjugated estrogens
    PhasePhase 1
    Registry statusCompleted

  • Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens

    NCT00550303 · start 2007-10

    Registered record
    Registry ID
    NCT00550303
    Conditions
    Healthy
    Interventions
    bazedoxifene/conjugated estrogens combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-10
    Completion
    2007-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionbazedoxifene/conjugated estrogens combination
    PhasePhase 1
    Registry statusCompleted

  • Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

    NCT00479778 · start 2007-04

    Registered record
    Registry ID
    NCT00479778
    Conditions
    Postmenopause
    Interventions
    Bazedoxifene/conjugated estrogens
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-04
    Completion
    2007-07
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause
    InterventionBazedoxifene/conjugated estrogens
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women

    NCT00464789 · start 2007-03

    Registered record
    Registry ID
    NCT00464789
    Conditions
    Menopause
    Interventions
    Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-05
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause
    InterventionBazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women

    NCT00465075 · start 2007-03

    Registered record
    Registry ID
    NCT00465075
    Conditions
    Healthy
    Interventions
    Bazedoxifene/conjugated estrogens combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBazedoxifene/conjugated estrogens combination
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women

    NCT00396799 · start 2006-11

    Registered record
    Registry ID
    NCT00396799
    Conditions
    Menopause
    Interventions
    bazedoxifene/conjugated estrogens
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-11
    Completion
    2006-11
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause
    Interventionbazedoxifene/conjugated estrogens
    PhasePhase 1
    Registry statusCompleted

  • Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

    NCT00418236 · start 2006-10

    Registered record
    Registry ID
    NCT00418236
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-10
    Completion
    2010-04
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution

    NCT00367536 · start 2006-08

    Registered record
    Registry ID
    NCT00367536
    Conditions
    Postmenopause
    Interventions
    bazedoxifene/conjugated estrogens combination tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2006-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause
    Interventionbazedoxifene/conjugated estrogens combination tablet
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women

    NCT00384072 · start 2006-05

    Registered record
    Registry ID
    NCT00384072
    Conditions
    Postmenopause; Osteoporosis
    Interventions
    bazedoxifene BZA-20
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05
    Completion
    2007-09
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause; Osteoporosis
    Interventionbazedoxifene BZA-20
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

    NCT00234819 · start 2005-10

    Registered record
    Registry ID
    NCT00234819
    Conditions
    Vasomotor Symptoms Associated With Menopause
    Interventions
    Bazedoxifene/Conjugated Estrogen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-10
    Completion
    2007-02
    Enrolment
    325

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasomotor Symptoms Associated With Menopause
    InterventionBazedoxifene/Conjugated Estrogen
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

    NCT00238732 · start 2005-10

    Registered record
    Registry ID
    NCT00238732
    Conditions
    Vaginal Atrophy
    Interventions
    Bazedoxifene/Conjugated Estrogen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-10
    Completion
    2007-03
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVaginal Atrophy
    InterventionBazedoxifene/Conjugated Estrogen
    PhasePhase 3
    Registry statusCompleted